Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 8/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.41 |
| ▸ | QDPR | P09417 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24935704 | 0.82 | EPHX2 (0.42) | EPHX2EPHX1QDPRCYP1A2TDP1 | |
| SCHEMBL6107767 | 0.79 | EPHX2 (0.43) | EPHX2EPHX1QDPRCYP1A2TDP1 | |
| SCHEMBL19498073 | 0.77 | EPHX2 (0.41) | EPHX2EPHX1QDPRCYP1A2TDP1 | |
| SCHEMBL23509414 | 0.77 | PIK3CD (0.39) | EPHX2EPHX1QDPRCYP1A2TDP1 | |
| SCHEMBL57711 | 0.77 | CYP1A2 (0.44) | EPHX2EPHX1QDPRCYP1A2TDP1 | |
| SCHEMBL3764738 | 0.75 | EPHX2 (0.43) | EPHX2EPHX1QDPRCYP1A2TDP1 | |
| SCHEMBL27270646 | 0.74 | EPHX2 (0.37) | EPHX2EPHX1CYP1A2TDP1 | |
| SCHEMBL21472126 | 0.72 | CYP1A2 (0.48) | EPHX2EPHX1QDPRCYP1A2TDP1 | |
| SCHEMBL20255973 | 0.72 | CYP1A2 (0.48) | EPHX2EPHX1QDPRCYP1A2TDP1 | |
| SCHEMBL329321 | 0.71 | CYP1A2 (0.52) | EPHX2EPHX1QDPRCYP1A2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220153732-A1 | PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153732-A1 | PROTEIN SECRETION INHIBITORS | SEC61B, SEC61A1, SEC61G | EPHX2 3730/4885EPHX1 3446/4885QDPR 3903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.